StockData
Lexicon Pharmaceuticals, Inc. logo

Lexicon Pharmaceuticals, Inc. (LXRX) shareholders

LXRXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 5/3087% above fair value
$1.78+0.03 (+1.71%)

Close on Nov 17, 2026Market cap $792.02MP/E –Yield –

Ownership

Institutional holdings as of Jun 30, 2026, from 13F filings

Held by institutions
81.9%
365M of 445M shares
Institutional holders
149
45 new, 30 sold out
Net institutional buying
41M
In Q2 2026
Insider trades, 12 months
9 buys · 0 sales
Net bought $2.77M

Shares held by institutions

Holders of more than 5%

Latest Schedule 13D (active) or 13G (passive) filed by each holder

HolderShares% of classFilingAs of
Stichting Administratiekantoor Westend
Joint filing with Amaury Wittouck (39.40%), Artal Participations S.a r.l. (39.40%) and 9 more
175,156,06239.40%13D (active) amendmentApr 30, 2026
Artal International Management S.A.
Joint filing with Mr. Amaury Wittouck (36.20%), Artal Participations S.a r.l. (36.20%) and 9 more
154,734,32736.20%13D (active) amendmentJan 29, 2026
FMR LLC
Joint filing with Abigail P. Johnson (15.00%)
66,743,39015.00%13G (passive) amendmentSep 30, 2026
Abigail P. Johnson
Joint filing with FMR LLC (10.50%)
38,137,53510.50%13G (passive) amendmentJun 30, 2025

Top institutional holders

13F holdings as of Jun 30, 2026

HolderShares% of LXRXValueChange% of portfolio
Artal Group S.A.175,156,06239.36%$420.37M+20,421,73545.15%
FMR LLC51,782,04511.64%$124.28M+6,725,7070.01%
Siren, L.L.C.44,303,5189.96%$106.33M–2.15%
Sessa Capital IM, L.P.18,960,8364.26%$45.51M+1,047,8750.76%
BlackRock, Inc.17,348,7413.90%$41.64M+14,026,5220.00%
Vanguard Capital Management LLC9,901,2082.23%$23.76M+382,0410.00%
Point72 Asset Management, L.P.8,251,3251.85%$19.80M+436,7190.02%
Geode Capital Management, LLC6,244,3721.40%$14.99M+3,075,2610.00%
State Street Corp4,917,7691.11%$11.80M+3,953,7310.00%
Vanguard Portfolio Management LLC2,357,7490.53%$5.66M+1,811,1490.00%
Northern Trust Corp1,968,6190.44%$4.72M+1,473,9530.00%
Charles Schwab Investment Management Inc1,956,7750.44%$4.70M+645,4770.00%
Vanguard Fiduciary Trust Co1,634,5710.37%$3.92M+302,2870.00%
Citadel Advisors LLC1,601,1820.36%$3.84M+506,2810.00%
Ishara Investments LP1,271,0000.29%$3.05M+369,0002.24%
Millennium Management LLC1,134,2290.25%$2.72M−3,810,5020.00%
Renaissance Technologies LLC1,127,0000.25%$2.70M−473,5000.00%
Mackenzie Financial Corp963,3540.22%$2.31M+190,6770.00%
ADAR1 Capital Management, LLC750,0000.17%$1.80M–0.08%
Susquehanna International Group, Llp696,7760.16%$1.67M−1,424,3880.00%

Institutional buying and selling by quarter

Positions opened, added to, reduced and closed by 13F filers

QuarterHoldersShares held% of sharesNew / addedReduced / closedShares boughtShares sold
Q2 2026149365M81.9%45 / 3636 / 3061M20M
Q1 2026136323M72.7%31 / 4126 / 1578M3M
Q4 2025125260M58.5%23 / 2841 / 1712M6M
Q3 2025123255M57.3%18 / 2642 / 179M11M
Q2 2025123257M57.8%29 / 3136 / 3316M25M
Q1 2025127266M59.7%31 / 3432 / 2911M42M
Q4 2024127298M66.9%25 / 4524 / 3429M20M
Q3 2024137289M64.9%26 / 4621 / 1474M57M
Q2 2024127281M63.2%26 / 4822 / 17114M6M
Q1 2024118173M39.0%33 / 3131 / 2022M36M
Q4 2023106187M42.0%25 / 3024 / 3114M16M
Q3 2023112189M42.4%11 / 4530 / 215M7M

Top mutual fund and ETF holders

Latest monthly portfolio reports (Form N-PORT)

72 funds held LXRX in Q2 2026, 42% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.

FundShares% of LXRXValue% of fundAs of
Fidelity Growth Company Fund16,542,0003.72%$36.06M0.04%May 31, 2026
Vanguard Total Stock Market Index Fund7,083,6511.59%$17.00M0.00%Jun 30, 2026
iShares Russell 2000 ETF6,209,9441.40%$14.90M0.02%Jun 30, 2026
Fidelity Growth Company K6 Fund4,887,3061.10%$10.65M0.04%May 31, 2026
Fidelity Series Growth Company Fund3,977,6930.89%$8.67M0.04%May 31, 2026
Fidelity Small Cap Index Fund2,722,9890.61%$6.29M0.02%Jul 31, 2026
Vanguard Extended Market Index Fund2,567,3100.58%$6.16M0.01%Jun 30, 2026
iShares Russell 2000 Growth ETF2,278,2910.51%$5.47M0.04%Jun 30, 2026
State Street(R) SPDR(R) S&P(R) Pharmaceuticals ETF1,121,9880.25%$2.69M0.63%Jun 30, 2026
Fidelity Extended Market Index Fund1,112,8340.25%$2.43M0.01%May 31, 2026
Schwab U.S. Small-Cap ETF1,032,2230.23%$2.25M0.01%May 31, 2026
iShares Micro-Cap ETF835,5300.19%$2.01M0.13%Jun 30, 2026
Schwab Small-Cap Index Fund604,4130.14%$1.40M0.02%Jul 31, 2026
Vanguard Health Care Index Fund544,1990.12%$1.19M0.01%May 31, 2026
Select Biotechnology Portfolio515,3000.12%$1.12M0.02%May 31, 2026

Officers, directors and major owners

People who filed Forms 3, 4 or 5 in the last two years

NameRoleShares owned% of sharesLatest filing
Michael ExtonChief Executive Officer, Director328,4960.07%Nov 9, 2026
Brian T. CrumSVP, General Counsel & Secr.330,2010.07%Mar 3, 2026
Lisa DeFrancescoSVP, IR and Corp Comm40,2510.01%Mar 3, 2026
Rachel Yap MartensSVP, Partnerships & Corp Strat67,0900.02%Mar 3, 2026
Suma GopinathanSVP, Discovery88,5200.02%Mar 3, 2026
Scott M. CoianteSVP, Chief Financial Officer105,3560.02%Mar 3, 2026
Craig B. GranowitzSVP, Chief Medical Officer432,5280.10%Mar 3, 2026
Wendy McDermottSVP, Human Resources277,9450.06%Mar 3, 2026
Kristen AlexanderVP, Finance and Accounting76,3680.02%Mar 3, 2025
Alan J. MainEVP, Innov & Chem Sciences281,3910.06%Mar 3, 2025
Brian CorriganSVP, Regulatory & QA––Feb 18, 2025
Diane E. SullivanDirector126,1220.03%Jun 4, 2026
Judith L. SwainDirector174,4860.04%Jun 4, 2026
Ivan CheungDirector89,3120.02%Jun 4, 2026
Sam L. BarkerDirector248,7710.06%Jun 4, 2026
Raymond DebbaneDirector51,750,22111.63%Jun 4, 2026
Philippe AmouyalDirector374,4860.08%Jun 4, 2026
Christopher J. SobeckiDirector293,1770.07%Jun 4, 2026
S.A. WestendDirector, 10% owner3,333,3760.75%May 8, 2026
Administratiekantoor Westend StichtingDirector, 10% owner1,150,9220.26%May 8, 2026
International Management S.A. ArtalDirector, 10% owner3,006,6780.68%May 8, 2026
International S.C.A. ArtalDirector, 10% owner408,4350.09%May 8, 2026
Group S.A. ArtalDirector, 10% owner367,1450.08%May 8, 2026
Amaury WittouckDirector, 10% owner3,516,2140.79%May 8, 2026
Participations S.a r.l. ArtalDirector, 10% owner311,336,54369.97%May 8, 2026
Life Sci Master GP LLC AvicennaDirector, 10% owner1,538,4620.35%Feb 12, 2026
Life Sci Master Fund LP AvicennaDirector, 10% owner––Feb 12, 2026
Invus Global Management, LLCDirector, 10% owner––Feb 4, 2026
Siren, L.L.C.Director, 10% owner35,402,6897.96%Feb 4, 2026

Insider trades

Common stock transactions reported on Form 4, newest first

InsiderDateTransactionSharesPriceValueShares after
Michael Exton
Chief Executive Officer, Director
Nov 6, 2026Buy+30,064$1.66$50.00K328,496
Diane E. Sullivan
Director
Jun 3, 2026Option exercise+89,312––126,122
Ivan Cheung
Director
Jun 3, 2026Option exercise+89,312––89,312
Raymond Debbane
Director
Jun 3, 2026Option exercise+89,312––1,995,498
Sam L. Barker
Director
Jun 3, 2026Option exercise+89,312––213,771
Judith L. Swain
Director
Jun 3, 2026Option exercise+89,312––174,486
Christopher J. Sobecki
Director
Jun 3, 2026Option exercise+89,312––293,177
Philippe Amouyal
Director
Jun 3, 2026Option exercise+89,312––374,486
Participations S.a r.l. Artal
Director, 10% owner
Apr 30, 2026Option exercise+20,421,735––175,156,062
Suma Gopinathan
SVP, Discovery
Feb 28, 2026Option exercise+14,000––88,520
Suma Gopinathan
SVP, Discovery
Feb 28, 2026Option exercise+20,310––108,830
Suma Gopinathan
SVP, Discovery
Feb 28, 2026Tax withholding−24,338$1.47$35.78K150,132
Suma Gopinathan
SVP, Discovery
Feb 28, 2026Option exercise+65,640––174,470
Scott M. Coiante
SVP, Chief Financial Officer
Feb 28, 2026Tax withholding−54,881$1.47$80.68K105,356
Scott M. Coiante
SVP, Chief Financial Officer
Feb 28, 2026Option exercise+160,237––160,237
Lisa DeFrancesco
SVP, IR and Corp Comm
Feb 28, 2026Option exercise+24,674––40,251
Lisa DeFrancesco
SVP, IR and Corp Comm
Feb 28, 2026Option exercise+128,190––168,441
Lisa DeFrancesco
SVP, IR and Corp Comm
Feb 28, 2026Tax withholding−74,572$1.47$109.62K93,869
Rachel Yap Martens
SVP, Partnerships & Corp Strat
Feb 28, 2026Option exercise+67,090––67,090
Rachel Yap Martens
SVP, Partnerships & Corp Strat
Feb 28, 2026Tax withholding−35,826$1.47$52.66K31,264
Michael Exton
Chief Executive Officer, Director
Feb 28, 2026Option exercise+503,263––503,263
Michael Exton
Chief Executive Officer, Director
Feb 28, 2026Tax withholding−204,831$1.47$301.10K298,432
Wendy McDermott
SVP, Human Resources
Feb 28, 2026Tax withholding−68,107$1.47$100.12K277,945
Wendy McDermott
SVP, Human Resources
Feb 28, 2026Option exercise+144,393––346,052
Wendy McDermott
SVP, Human Resources
Feb 28, 2026Option exercise+27,697––149,343
Wendy McDermott
SVP, Human Resources
Feb 28, 2026Option exercise+52,316––201,659
Brian T. Crum
SVP, General Counsel & Secr.
Feb 28, 2026Option exercise+69,386––330,201
Brian T. Crum
SVP, General Counsel & Secr.
Feb 28, 2026Tax withholding−105,019$1.47$154.38K428,802
Brian T. Crum
SVP, General Counsel & Secr.
Feb 28, 2026Option exercise+33,457––363,658
Brian T. Crum
SVP, General Counsel & Secr.
Feb 28, 2026Option exercise+170,163––533,821
Craig B. Granowitz
SVP, Chief Medical Officer
Feb 28, 2026Option exercise+202,260––432,528
Craig B. Granowitz
SVP, Chief Medical Officer
Feb 28, 2026Tax withholding−109,098$1.47$160.37K323,430
Craig B. Granowitz
SVP, Chief Medical Officer
Feb 28, 2026Option exercise+74,226––230,268
Craig B. Granowitz
SVP, Chief Medical Officer
Feb 28, 2026Option exercise+35,790––156,042
Raymond Debbane
Director
Feb 25, 2026Buy+2,000$1.49$2.98K1,906,186
Raymond Debbane
Director
Feb 23, 2026Buy+100,000$1.47$147.00K1,904,186
Raymond Debbane
Director
Feb 20, 2026Buy+100,000$1.48$148.00K1,804,186
Raymond Debbane
Director
Feb 19, 2026Buy+50,000$1.44$72.00K1,704,186
Raymond Debbane
Director
Feb 18, 2026Buy+133,688$1.32$176.47K1,654,186
International S.C.A. Artal
Director, 10% owner
Feb 17, 2026Award+41,289.58$65.00$2.68M408,435
Raymond Debbane
Director
Feb 17, 2026Buy+76,857$1.31$100.68K1,520,498
Raymond Debbane
Director
Feb 13, 2026Buy+57,952$1.31$75.92K1,443,641
Group S.A. Artal
Director, 10% owner
Feb 2, 2026Award+367,145.12$65.00$23.86M367,145
Group S.A. Artal
Director, 10% owner
Feb 2, 2026Award+18,553,846$1.30$24.12M154,734,327
Group S.A. Artal
Director, 10% owner
Feb 2, 2026Award+3,846,154$1.30$5.00M7,362,368
Group S.A. Artal
Director, 10% owner
Feb 2, 2026Buy+1,538,462$1.30$2.00M1,538,462
Christopher J. Sobecki
Director
May 13, 2025Option exercise+36,810––203,865
Sam L. Barker
Director
May 13, 2025Option exercise+36,810––124,459
Judith L. Swain
Director
May 13, 2025Option exercise+36,810––85,174
Diane E. Sullivan
Director
May 13, 2025Option exercise+36,810––36,810
Philippe Amouyal
Director
May 13, 2025Option exercise+36,810––285,174
Raymond Debbane
Director
May 13, 2025Option exercise+36,810––1,385,689
Brian T. Crum
SVP, General Counsel & Secr.
Feb 28, 2025Tax withholding−45,622$0.67$30.57K260,815
Brian T. Crum
SVP, General Counsel & Secr.
Feb 28, 2025Option exercise+69,387––306,437
Brian T. Crum
SVP, General Counsel & Secr.
Feb 28, 2025Option exercise+33,456––237,050
Brian T. Crum
SVP, General Counsel & Secr.
Feb 28, 2025Option exercise+26,097––203,594
Lisa DeFrancesco
SVP, IR and Corp Comm
Feb 28, 2025Option exercise+24,673––24,673
Lisa DeFrancesco
SVP, IR and Corp Comm
Feb 28, 2025Tax withholding−9,096$0.67$6.09K15,577
Alan J. Main
EVP, Innov & Chem Sciences
Feb 28, 2025Option exercise+25,667––281,391
Alan J. Main
EVP, Innov & Chem Sciences
Feb 28, 2025Option exercise+32,904––314,295

Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.

Short interest

Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)

Short % of shares outstanding
5.82%
26M shares short
Days to cover
14.0
At 2M shares a day
Change since last report
-3.1%
From 27M shares
Short volume, 20 days
60.1%
Of volume reported to FINRA

Shares sold short, last 12 months

Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Lexicon Pharmaceuticals's stock actually held short. Settlement fails (shares not delivered on time) peaked at 124,382 shares on Aug 24, 2026 over the last 90 days.

Planned insider sales

Notices of proposed sale filed on Form 144 before shares are sold

SellerFiledSharesMarket valuePlanned saleAcquired through
Lonnel Coats
Former Affiliate
Aug 15, 2024300,000$480.00KAug 15, 2024Restricted Stock Lapse - see remarks
Seth Kiernan
Former Affiliate
Jul 12, 202319,000$43.89KJul 12, 2023Restricted Stock Lapse

See a number that looks wrong?